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Abstract
Chronic obstructive pulmonary disease (COPD) is a global health problem, and current therapy for
COPD is poorly effective and the mainstays of pharmacotherapy are bronchodilators. A better
understanding of the pathobiology of COPD is critical for the development of novel therapies. In
the present review, we have discussed the roles of oxidative/aldehyde stress, inflammation/
immunity, and chromatin remodeling in the pathogenesis of COPD. Imbalance of oxidant/
antioxidant balance caused by cigarette smoke and other pollutants/biomass fuels plays an
important role in the pathogenesis of COPD by regulating redox-sensitive transcription factors
(e.g. NF-κB), autophagy and unfolded protein response leading to chronic lung inflammatory
response. Cigarette smoke also activates canonical/alternative NF-κB pathways and their upstream
kinases leading to sustained inflammatory response in lungs. Recently, epigenetic regulation has
been shown to be critical for the development of COPD because the expression/activity of
enzymes that regulate these epigenetic modifications have been reported to be abnormal in
airways of COPD patients. Hence, the significant advances made in understanding the
pathophysiology of COPD as described herein will identify novel therapeutic targets for
intervening COPD.
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INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is a major and increasing global health
problem and is the fourth commonest cause of death in the developed countries. It is a
disabling condition associated with progressive breathlessness. COPD will account for over
6 million deaths per year by 2020 and is predicted to take a leap from the sixth- to the third-
leading cause of death worldwide. In America, COPD affects 9% of residents aged 60 years
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and above and is ranked fourth in the recent morbidity survey of the elderly population. It is
estimated that approximately 23.4 million people in the USA have COPD and the health
burden is $36.1 billions per year. The burden of COPD for the patient is high as patients
experience a poorer quality of life, suffer from comorbidites (3.7 comorbidities per patient),
and direct healthcare amounted to 20.9 billion dollar in the USA in 2004.
Cigarette smoke is the major risk factor for the development of COPD. It is likely to account
for ~80%–90% of COPD cases in USA (Sethi and Rochester, 2000). Cigarette smoke
contains an estimated 1015–1017 oxidants/free radicals and ~4,700 different chemical
compounds, including reactive aldehydes and quinones, per puff (Church and Pryor, 1985).
Cigarette smoke is the primary cause of COPD (emphysema and chronic bronchitis)
characterized by accelerated decline in lung function, inflammation and premature aging of
the lung. However, only 10%–20% of the smokers develop COPD pointing at an additional
risk factor such as genetic susceptibility, e.g. the polymorphisms in genes coding for (anti-)
proteases like alpha-1 antitrypsin (1AAT), a disintegrin and metalloproteinase 33
(ADAM33), or antioxidant superoxide dismutase (SOD), and pro-inflammatory mediators
tumor necrosis factor-α (TNF-α) (Harrison et al., 1997; Keatings et al., 2000; Sandford et
al., 2001; Kucukaycan et al., 2002; Celedon et al., 2004; Young et al., 2006). Other noxious
environmental gases/particles such as NO2, SO2, and particulate matters, as well as exposure
to second hand tobacco hand smoke and biomass fuel can also cause oxidative stress and
trigger inflammatory responses in the lungs in a susceptible population. Cessation of
smoking reduces progression of the disease only if applied early and has little effect after
significant symptoms ensues. At present, no effective treatment exists to halt the decline in
lung function in smokers who get the disease. This in turn reflects a lack of understanding of
the specific cellular and biochemical pathways triggered in the lung by tobacco smoke.
Thus, it is essential that COPD research should focus on improving our understanding of the
specific cellular and biochemical injury induced by tobacco smoke within the lung. Most
treatments for COPD are mainly palliative, and no single therapy exists that can halt the
decline in lung function or progressive destruction of the airways. The mainstays of
pharmacotherapy are bronchodilators (to relieve the symptoms of bronchoconstriction),
corticosteroids (to reduce the airway inflammation), and combination of bronchodilators
with corticosteroids. However, current corticosteroid therapy in COPD is poorly effective
(Barnes et al., 2004). This has prompted an intense search for new anti-inflammatory
therapeutic targets based on a better understanding of the underlying pathophysiology of
COPD.
PATHOGENESIS
COPD is a preventable and treatable disease with some significant extrapulmonary effects
that may contribute to severity in individual patients. Its pulmonary component is
characterized by airflow limitation that is not fully reversible, and the airflow limitation is
usually progressive and associated with an abnormal inflammatory response of the lung to
noxious particles or gases (Rabe et al., 2007). COPD can be classified into 4 classes of
severity based on lung function [GOLD Guidelines]. Emphysema, chronic bronchitis with
airway obstruction, and small airways disease are the distinct phenotypes of COPD, but
most patients show a combination of different phenotypes. Emphysema is characterized by a
Th1 type inflammation, destruction of the alveolar septs, loss of elastic recoil, airspace
enlargement and hence loss of gas diffusion capacity (Wright and Churg, 2006). Chronic
bronchitis affects the large airways by airway inflammation, goblet cell hyperplasia and
mucus hypersecretion. In addition to decreased lung function, these patients experience
chronic sputum production, coughing and often dyspnoea. Small airways disease mainly
affects the bronchioles featuring airway inflammation and metaplasia of Clara cells.
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The pathogenesis of COPD involves several pathogenetic processes, such as oxidative
stress, inflammation, protease/antiprotease imbalance, alteration in immunity (autoantibody
production), apoptosis, alteration of cell proliferation, and cellular senescence/aging,
induced by air pollutants, modified by genetic factors, and exacerbated by virus and bacteria
(Shapiro and Ingenito, 2005; El Moussaoui et al., 2008; Kang et al., 2008; Tuder and Yun,
2008; MacNee and Tuder, 2009; Sethi et al., 2009). This review focuses on specific
molecules that regulate oxidative stress, inflammatory response, and epigenetics and their
mechanisms/consequences so as to provide the possible therapies against these targets for
intervention in COPD.
OXIDATIVE AND ALDEHYDE/CARBONYL STRESS IN COPD
Formation of reactive and unstable free radicals such as superoxide anion (O2•−), nitric
oxide, peroxynitrite (ONOO−) and hydroxyl radicals (•OH) lead to a series of chain
reactions which yields uncontrolled (if not ablated) tissue destruction as a result of
oxidation. The importance of oxidative stress has been confirmed by several studies that
have identified the presence of free radical biomarkers in patients with COPD. Increased
level of 8-hydroxy-deoxyguansoine was detected in urine of COPD patients, and elevated
level of 3-nitrotyrosine and F2α isoprostanes occurred in lungs of COPD patients, and these
markers demonstrated a strong correlation with disease severity as measured by forced
expiratory volume in the first second (FEV1) (Ichinose et al., 2000; Rahman et al., 2002;
Igishi et al., 2003). Furthermore, the levels of lipid peroxidation products 4-hydroxynonenal
(4-HNE) and malondialdehyde (MDA) were increased in lungs of patients with COPD, and
this increase was negatively correlated with lung function (Rahman et al., 2002; Harju et al.,
2004; Rytila et al., 2006). These reactive aldehydes deplete thiol pool, carbonylate proteins
or form aldehye-protein adducts leading to alteration of protein function and causing a
variety of cellular and biochemical effects including immunogenicity and proteolysis
thereby inducing lung inflammatatory and autoimmune responses, and injury (Fig. 1). Thus,
redressing of oxidant/antioxidant imbalance and reducing lipid peroxidation will be able to
prevent the progression of COPD as shown previously (Kinnula, 2005; De Boer et al.,
2007b).
Exogenous and endogenous ROS production
There are essentially two sources of reactive oxygen species (ROS) and reactive nitrogen
species (RNS) that the lungs are exposed to, environmental and cellular. The single most
important environmentally derived ROS in driving the pathogenesis of COPD is cigarette
smoke. ROS/RNS are also generated by several inflammatory and structural cells of the
airways. One of the features of COPD is an inflammatory-immune response, characterized
by activation of epithelial cells, and resident macrophages, and the recruitment and
activation of neutrophils, monocytes, and B- and T- lymphocytes. Inflammatory cells once
recruited in the airspace become activated and generate ROS in response to a sufficient level
of a secretagogue stimulus (threshold condition). The principle ROS-generating enzyme in
inflammatory cells is NADPH oxidase. Other enzyme systems such as the xanthine/xanthine
oxidase system and the heme peroxidases are also involved in COPD (Rahman et al., 1996;
Pinamonti et al., 1998). Similarly, RNS in the form of nitric oxide (NO) production is
generated by nitric oxide synthase. Moreover, nitric oxide will form the more potent and
damaging peroxynitrite molecules in the presence of superoxide anion. Interestingly, we and
others have shown that disruption of p47phox and gp91phox, the components of NADPH
oxidase, resulted in airspace enlargement in mice (Kassim et al., 2005; Yao et al., 2008b)
suggesting ROS-derived from NADPH oxidase participate in signaling pathway of tissue
homeostasis, and the use of NADPH oxidase inhibitor for redressing the oxidant/antioxidant
imbalance in COPD may be deleterious.
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Antioxidant defense in COPD
Under normal condition, the lungs have well coordinated and efficient endogenous
antioxidant defense systems, which protect against the injurious effects of oxidants by
electron transfer, enzymatic removal, scavenging and by keeping transition metal ions
tightly sequestered. Furthermore, a variety of enzymes including aldehyde dehydrogenase
and aldo-keto reductase, which are responsible for the detoxification of reactive aldehydes
such as acetaldehyde and acrolein, were significantly induced in mouse lung exposed to
cigarette smoke (Rangasamy et al., 2004), but their role in lungs of chronic smokers and in
pathogenesis of COPD is not known. These phase I enzymes decarbonylate proteins and
thereby reverse their post-translational modifications caused by reactive aldehydes (4-HNE,
acrolein, and acetaldehyde). Nevertherless, it has been shown that increased ROS production
and reduced endogenous antioxidant defense has been reported in several lung diseases
including COPD (Repine et al., 1997; Macnee and Rahman, 1999; Rahman and MacNee,
2000; Tomaki et al., 2007). In patients with COPD, this balance may be disturbed due to
mutations in genes encoding for antioxidant enzymes, such as extracellular SOD,
glutathione S-transferase M1 (GSTM1), GSTT1, GSTP1, and glutamate cysteine ligase
(GCL) (Harju et al., 2002; He et al., 2002; Kinnula, 2005; Juul et al., 2006; Young et al.,
2006; Mak et al., 2007; Siedlinski et al., 2008). Recent animals studies showed that Cu/Zn
SOD protected cigarette smoke-, elastase- and ceramide-induced emphysema in mice
(Foronjy et al., 2006; Petrache et al., 2008). Likewise, overexpression of extracellular SOD
attenuated acute cigarette smoke-mediated lung inflammatory response and elastase-induced
emphysema in mice (Yao et al, unpublished work). Indeed, the dead space volume/total lung
capacity was increased which reflects a reduction of ventilation efficiency in extracellular
SOD deficient mice compared to WT mice (Ganguly et al., 2007). Furthermore, acute
reduction of extracellular SOD using cre-lox homologous recombination (conditional
knockout) led to an increase in lung superoxide, marked inflammatory cell infiltration, the
arterial-alveolar gradient, respiratory acidosis, histological changes similar to those observed
in adult respiratory distress syndrome, and 85% mortality (Gongora et al., 2008). Treatment
with the SOD mimetic MnTBAP and intranasal administration of SOD-containing polyketal
microparticles reduced mortality, prevented the histological alterations, and reduced lung
superoxide levels (Gongora et al., 2008). In addition, the polymorphisms of extracellular
SOD gene was associated with reduced lung function or lower risk of COPD (Young et al.,
2006; Dahl et al., 2008). These results suggested that antioxidant therapy would seem to be
a logical therapeutic approach in COPD. The use of a variety of antioxidants, such as SOD
mimetics, mucolytic agents, such as N-acetyl-L-cysteine (NAC, a cellular precursor of
GSH) and erdosteine, has met with varying success in patients with COPD (Dekhuijzen,
2004; Moretti et al., 2004; Decramer et al., 2005; van Overveld et al., 2005).
It has been shown that the protein but not mRNA level of nuclear erythroid-related factor 2
(Nrf2), a transcription factor upregulating phase II genes, was decreased in lungs of patients
with COPD/emphysema, and deficiency of Nrf2 resulted in enhanced susceptibility to
cigarette smoke- and elastase-induced emphysema in mice which is associated with more
pronounced oxidative stress in lungs (Rangasamy et al., 2004; Iizuka et al., 2005; Ishii et al.,
2005; Goven et al., 2008; Malhotra et al., 2008; Suzuki et al., 2008; Cho and Kleeberger,
2009; Singh et al., 2009). Therefore, modulation of Nrf2 would be expected to have
significant beneficial effects in cigarette smoke-mediated oxidative stress and lung
inflammation. The reduction of Nrf2 was corroborated with our findings showing
attenuation of posttranslational modification of Nrf2 by resveratrol, a polyphenolic
phytoalexin present in red wine, protected against cigarette smoke-mediated oxidative stress
in human epithelial cells (Kode et al., 2008). It was associated with nuclear translocation of
Nrf2, thereby leading to induction of GCL, a rate-limiting enzyme for the synthesis of
glutathione. Silencing of DJ-1, a stabilizer of Nrf2, in mouse lungs, mouse embryonic
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fibroblasts and Beas2B cells impaired antioxidant induction in response to cigarette smoke
(Malhotra et al., 2008). Genetic deletion of KEAP1, a cytosolic inhibitor of Nrf2, in Clara
cells attenuated cigarette smoke-inudced inflammation and oxidative stess in mouse lung
(Blake et al., 2009). Therefore, enhancement of DJ-1 would stabilize Nrf2 protein
promoting the expression of key antioxidant enzymes in response to cigarette smoke. It is
interesting to note that the level of DJ-1 was reduced and post-translationally modified in
COPD lungs but not in those of normal smokers. Recently, it has been shown that wild-type
mice exposed to cigarette smoke, when treated with CDDO-Im [imidazole and methyl ester
derivative of 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid (CDDO)] exhibited
significant reductions in both oxidative stress and alveolar destruction with increased
transcriptional induction of multiple Nrf2-regulated antioxidant genes (Biswal et al., 2008;
Sussan et al., 2009). However, Nrf2 knockout mice had no significant reduction in alveolar
destruction following treatment with CDDO-Im (Biswal et al., 2008; Sussan et al., 2009).
These data suggest that activation of the Nrf2 pathway, stabilization of DJ1 and reversing
posttranslational carbonyl modifications of Nrf2, Keap1 and DJ1 using different approaches
can be developed to protect lungs against cigarette smoke/oxidative stress-induced
inflammatory response and emphysema.
Oxidative/aldehyde stress-mediated neurogenic inflammation in lungs
Transient receptor potential cation channel, subfamily A, member 1 (TRPA1) is an
excitatory ion channel expressed by a subpopulation of primary afferent somatosensory
neurons that contain substance P and calcitonin gene-related peptide. TRPA1 can be
activated by a range of highly reactive chemicals, such as H2O2 and α,β-unsaturated
aldehydes [acrolein, crotonaldehyde, and 4-hydroxy-2-nonenal (4-HNE)] eliciting pain or
promoting immediate protective responses (Trevisani et al., 2007; Andersson et al., 2008).
These reactive chemicals, contained in cigarette smoke or generated by lipid peroxidation in
lungs of patients with COPD, are responsible for initiating and maintaining lung
inflammatory response (Rahman et al., 2002; Facchinetti et al., 2007; Borchers et al., 2008).
Recent studies showed that disruption of TRPA1 gene attenuated H2O2- and hypochlorite-
induced respiratory despression as well as oxidant-induced pain behavior suggesting TPRA1
is a major neuronal sensor for H2O2 and hypochlorite in the airways (Bessac et al., 2008).
Most importantly, cigarette smoke has the unique ability to excite capsaicin-sensitive
primary sensory neurons by activating TPRA1 to induce neurogenic inflammation in the
airway, and acrolein and crotonaldehyde are major mediators in cigarette smoke-induced
activation of TPRA1-expressing neurons (Andre et al., 2008). Therefore, topical application
of specific TPRA1 antagonists to airways would benefit those peoples who are exposed to
pollutants, especially with manifest aiways hypersensitivities (Simon and Liedtke, 2008).
Oxidative stress-mediated lung cell autophagy and apoptosis in COPD
Autophagy is a dynamic process responsible for the turnover of cellular organelles and long-
living proteins, which has been suggested to be an essential function to maintain cell
homeostasis and confer adaption to adverse environment. It has been shown that
accumulation of ROS led to autophagy to overcome oxidative stress (Scherz-Shouval et al.,
2007a; Scherz-Shouval et al., 2007b). This pathway is involved in the removal and
degradation of damaged mitochrondria and oxidized proteins. For example, sirtuin 1
(SIRT1), a class III histone deacetylase, is suggested to clear the old and damaged
mitochrondia by inducing autophagy. SIRT1 also increases the supply of new mitochrondia
by activating peroxisome proliferator-activated receptor γ coactivator-1α (PGC-α), the
mitochrondial biogenesis regulator (Lee et al., 2008). However, excessive autophagy will
lead to cell death. A recent study showed that increased autophagy occurred in lungs of
patients with COPD, in mouse lung tissues exposed to cigarette smoke, and in cells treated
with cigarette smoke extract (Chen et al., 2008; Ryter et al., 2009) which may be due to the
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reduction of SIRT1 in COPD (Rajendrasozhan et al., 2008b; Nakamaru et al., 2009)
suggesting a pivotal role of autophagy in the pathogenesis of COPD. Overexpression of
extracellular SOD attenuated the levels of early growth response protein-1 (Egr-1) gene and
protein which is an important transcription factor in autophagy in lungs in response to
hypoxia (Nozik-Grayck et al., 2008). It is interesting to note that inhibition of histone
deacetylase (HDAC, in particular HDAC6) activity resulted in the complex formation of
Egr-1 with E2F-4, leading to increased expression of microtubule-associated protein light
chain 3 (LC3), a best characterized autophagy protein (Chen et al., 2008). Therefore,
cigarette smoke-mediated decrease of HDAC activity leads to the transcriptional activation
of Egr-1 and E2F-4, thereby inducing autophagic cell death. These results suggested that
modulation of autophagic pathway may be beneficial in the intervention of COPD.
Oxidative stress-induced unfolded protein response in COPD
The unfolded protein response (UPR) is activated in response to an accumulation of
unfolded or misfolded proteins in the lumen of endoplasmic reticulum (ER). The UPR has
two primary aims: initially to restore normal function of the cell by preventing protein
translation and activate the signaling pathways that increase the production of molecular
chaperones involved in protein folding. When these objectives are not achieved within a
certain time lap or the disruption is prolonged, the UPR is to initiate apoptosis. During ER
stress, a chaperone Bip preferentially binds to unfolded or misfolded protein, leading to
disassociation of Bip with inositol-requiring 1α (IREα), double-stranded RNA-dependent
protein kinase-like ER kinase (PERK) and activating transcription factor 6 (ATF6) which
are the initiators of the three main signaling cascades of UPR. The activation of these three
pathways leads to transcription of UPR target genes encoding factors involved in amino-acid
biosythesis, the antioxidative stress response, apoptosis and inflammation (Gargalovic et al.,
2006; Zhang and Kaufman, 2008).
Recently, the expression of UPR markers such as ER chaperones, GRP78, calreticulin, ER
foldase and protein disulfide isomeras (PDI) were shown to be upregulated in lungs of
chronic cigarette smokers (Kelsen et al., 2008). This was confirmed by in vitro studies
showing the UPR was activated by gas phase and aqueous extract of cigarette smoke in
normal and malignant human lungs cells and mouse fibroblast cells (Hengstermann and
Muller, 2008; Jorgensen et al., 2008). Moreover, several downstream targets of the UPR
including antioxidant gene, thioredoxin-dependent peroxidase reductase were also increased
in lungs of these smokers. These results suggest that cigarette smoke-mediated UPR may be
a protective mechanism defending the lung against deleterious effects of cigarette smoke by
upregulating antioxidant molecules or down-regulating pro-inflammatory proteins
(Jorgensen et al., 2008; Kelsen et al., 2008). Indeed, Nrf2 was increased along with an
increase of GRP78, ATF4 and phosphorylated eIF2α in human bronchial epithelial cells (16-
HBE) in response to cigarette smoke extract (Kelsen et al., 2008). Furthermore, Nrf2 was a
direct substrate of PERK, and PERK-dependent Nrf2 phosphorylation triggers a dissociation
of Nrf2/Keap1 complexes and subsequent Nrf2 nuclear translocation (Cullinan et al., 2003;
Cullinan and Diehl, 2004). It also has been shown that activation of UPR may decrease the
inflammatory response to cigarette smoke since S100-A9/calgranulin C, an inflammatory
protein, was down-regualted in lungs of chronic smokers (Kelsen et al., 2008). This was
corroborated by the findings that inhibition of UPR in IRE1β knockout mice augmented
colonic inflammation in response to application of irritant chemicals to the colonic mucosa
(Bertolotti et al., 2001). However, the nature of stimuli that initiated the UPR in smokers is
not known. It has been shown that a variety of oxidant stimuli induced a UPR by increasing
cytosolic calcium and interfering with protein folding directly (Liu et al., 1998; van der
Vlies et al., 2002; Harding et al., 2003; Hung et al., 2003). Importantly, NAC and reduced
glutathione (GSH), the free radical scavengers, attenuated cigarette smoke-induced
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phosphorylation of eIF2α in A549 cells (Jorgensen et al., 2008). Therefore, ROS/aldehydes
present in cigarette smoke may contribute to the UPR in lungs of smokers, and antioxidants
and thiol compounds will ameliorate UPR leading to an attenuation of cell injury in response
to cigarette smoke.
INFLAMMATORY RESPONSE IN COPD
The chronic inflammation of COPD is characterized by an accumulation of neutrophils,
macrophages, B cells, lymphoid aggregates, CD4+, CD8+ T cells, and eosinophils,
particularly in the small airways (Turato et al., 2002; Hogg, 2004a; Saha and Brightling,
2006; Siva et al., 2007) (Fig. 2) and the degree of inflammation increases with the severity
of disease as classified by the GOLD guidelines (Hogg et al., 2004b).
Innate and adaptive immunity: new concept in pathogenesis of COPD
The innate defense system in lungs provides a rapid and initial response that can be triggered
by varieties of stimuli, but lacks in specificity, and has no memory. The cell components of
the innate immune system include neutrophils, macrophages, natural killer (NK) cells,
basophils, mast cells, eosinophils and others (Fig. 2). Cigarette smoke interferes with the
innate defense system by increasing mucus production, reducing mucociliary clearance,
disrupting the epithelial barrier and recruiting monocytes/macrophages and neutrophils into
the damaged lung tissue. These cells play an important role in the pathogenesis of COPD
through their potential release of ROS, cytokines, chemokines, elastase, and
metalloproteinase in response to cigarette smoke. Recent study showed that the aberrant and
persistant NK cell group 2D (NKG2D) ligand expression in the pulmonary epithelium
contributes to the development of COPD by activating its receptor on NK cells and CD8+
cells (Borchers et al., 2009). This suggests that the communication of pulmonary epithelium
with the immune system plays an important role in maintaining the integrity of lung tissue
and its aberration leads to altered inflammatory response. Cigarette smoke also stimulates
the cellular and humoral components of the adaptive immune response to provide a much
more specific reaction, which has precise memory for foreign materials previously exposed
to lungs (Fig. 2). However, it remains unclear why cells of adaptive immunity including B
lymphocytes, CD4+ and CD8+ T lymphocytes accumulate in lungs of smokers with COPD.
Organization of recruited lymphocytes into lymphoid follicles and the presence of
oligoclonal lymphocytes indicate that lymphocyte recruitment is a result of a targeted,
antigen-specific adaptive immune response, rather than of nonspecific trafficking of
lymphocytes to the lung (Hogg et al., 2004b;Sullivan et al., 2005;van der Strate et al.,
2006;Borchers et al., 2007;Borchers et al., 2008;Motz et al., 2008). Dendritic cells, antigen-
presenting cells, play an important role in the initiation and maintenance of adaptive
immune responses. Recent study showed that cigarette smoke impairs the normal maturation
of dendritic cells, and recruits a large number of circulating immature dendritic cells
precursors to the bronchial mucosa and lung parenchyma (Tsoumakidou et al., 2008). These
non- or partially matured and/or functionally impaired pulmonary dendritic cells reach the
draining lymph nodes or lymphoid follicles, and cooperate with naïve lymphocytes to induce
one of three predominant responses: Th1 (an increase of Th1 cytokines, and release of
perforin and granzymes, associated with apoptosis and necrosis of lung cells), Th2 (an
increase of IL-4 in and around mucus-secreting glands in patients with chronic bronchitis) or
Treg (an increase of TGF-β and the development of tolerance to infection in lung of patients
with COPD). Furthermore, dendritic cells retained antigen for presentation to T cells over
long periods where such chronic inflammation eventually results in emphysema.
Importantly, lung tissue damage associated with repeated cigarette smoke exposure may
unmask intracellular self-protein or alter normally nonantigenic proteins to be recognized as
nonself. Cross-presentation of self-antigen, such as elastin, endothelial antigens or epithelial
antigens by dendritic cells to CD8+ T cells could lead to the development of autoimmunity
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(Grumelli et al., 2004;Lee et al., 2007). It has been shown that carbonyl modifying proteins
have effectively altered the self protein so that it becomes naïve and highly immunogenic to
the immune system and hence generate antibodies against this altered non-self protein (e.g.
aldehyde-cigarette smoke containing reactive aldehyde modified proteins) (Allison and
Fearon, 2000) (Fig. 1). In doing this, because an antibody response is polyclonal there is
possibility of spill over so that some unaltered epitopes adjacent to the original carbonyl
modification epitopes which are not normally recognized, now become so-thereby breaking
the tolerance to these unaltered epitopes. In this way, B-cells may start producing altered
antibodies in response to cigarette smoke which occurs in patients with COPD (Lee et al.,
2007;Feghali-Bostwick et al., 2008). However, the pathways responsible for abnormal
antibody production form B-cells in response to cigarette smoke are not known. We have
recently showed that decreased RelB in B-cells in response to cigarette smoke would be the
key in signaling for altered antibody production (Yang et al., 2009).
Cytokines and chemokines
Chronic inflammation is one of the hallmarks of COPD. Lung inflammatory and structure
cells are known to release or produce proinflammatory cytokines including TNF-α,
interleukins (IL)-1β, 6, and 8 and interferons (IFNs) (De Boer, 2002). Previous reports
describe elevated levels of IL-1β, IL-6, CXCL8/IL-8, GM-CSF and TNF-α in either induced
sputum or BAL fluid or released from alveolar macrophages exposed to cigarette smoke in
patients with COPD (Keatings et al., 1996; Pesci et al., 1998; Vlahos et al., 2006; Saha et
al., 2009). Sputum neutrophils counts and level of IL-8 and circulating level of TNF-α are
the best markers relating to the severity of COPD (Franciosi et al., 2006). However, the
antibodies against IL-8 and TNF-α had little clinical effect in patients with COPD (Mahler et
al., 2004; Rennard et al., 2007; Dentener et al., 2008). On the contrary, the increased risk of
malignancies was seen in TNF-α antibody (infliximab)-treated subjects (Rennard et al.,
2007). Hence, it is crucial to develop the cytokines/chemokines antagonists/antibodies with
high selectivity and low toxicity for the intervention of COPD.
Recent studies highlighted the importance of IL-18 in pathogenesis of COPD. Cigarette
smoke caused activation of IL-18 signaling pathway in mice and human, and IL-18 protein
was strongly expressed in alveolar macrophages, CD8+ T-cells, and both the bronchiolar and
alveolar epithelial cells in the lungs of COPD patients (Kang et al., 2007; Petersen et al.,
2007; Imaoka et al., 2008). Furthermore, serum level of IL-18 in patients with GOLD stage
III and IV COPD was significantly higher than in smokers and nonsmokers. There was a
significant negative correlation between serum IL-18 level and the predicted FEV1 in
patients with COPD. Importantly, knockout of IL-18 receptor α subunit attenuated cigarette
smoke or cigarette smoke/poly (I:C)-mediated emphysema and lung inflammatory response
in mice (Kang et al., 2007; Kang et al., 2008) whereas constitutive overproduction of IL-18
in the lungs induced the emphysema and lung inflammatory response in mice suggesting the
pro-inflammatory and pro-emphysematous effect of IL-18 (Hoshino et al., 2007). It has been
shown that IL-18 plays an important role in Th1 polarization and various Th1-type diseases
(Dinarello, 1999; Gracie et al., 2003). Indeed, IL-18 also potentially induced Th2 cytokines
(IL-4, IL-5, IL-10, and IL-13), IgE, and IgG1 production (Hoshino et al., 1999; Hoshino et
al., 2000; Hoshino et al., 2007). Furthermore, targeting of IL-13 to the adult lung caused
emphysema in mice via a MMP- and cathepsin-dependent mechanism indicating Th2
inflammatory response also participates in the pathogenesis of COPD (Zheng et al., 2000;
van der Pouw Kraan et al., 2002; Miotto et al., 2003). Cigarette smoke selectively enhances
viral pathogen-associated molecular pattern (PAMP)-induced pulmonary inflammation,
apoptosis and remodeling leading to emphysema in mice (Kang et al., 2008). This effect was
mediated by early induction of type I IFN and IL-18, and later induction of IL-12/IL-23 p40
and IFN-γ, and the activation of double-stranded RNA-dependent protein kinase (PKR) and
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eukaryotic initiating factor-2α. This study suggests that cigarette smoke selectively
augments the airway and alveolar inflammatory and remodeling responses induced by viral
PAMPs and viruses in mouse lung.
IL-32 is a pro-inflammatory cytokine produced by T lymphocytes, natural killer cells,
epithelial cells, and blood monocytes (Kim et al., 2005; Netea et al., 2005). It induces other
pro-inflammatory cytokines/chemokines, such as TNF-α, IL-1β, IL-6, and IL-8 by means of
the activation of NF-κB and p38 MAPK (Kim et al., 2005; Netea et al., 2005). Previous
study showed that the level/expression of IL-32 was increased in lung tissue of patients with
COPD, where it was co-localized with TNF-α and correlated with the degree of airflow
obstruction (Calabrese et al., 2008). These results suggest that IL-32 is indeed implicated in
the characteristic immune response of COPD, with a possible impact on disease progression.
Chemokines can be subdivided into four subfamilies based on their structural homology
around 4 cysteine residues: -C-, -CC-, -CXC-, and -CX3C-, in which X substitutes for any
amino acid. They act via specific membrane-bound receptors resulting in the activation of
signal transduction pathways that lead to chemotaxis or other activities including
proliferation, differentiation, and survival. There are several chemokines including- CXC-
(CXCL1, CXCL5, CXCL7-11), and -CC- (CCL2-5, CCL7, CCL8, CCL11, CCL13)
involved in the recruitment of inflammatory cells in COPD (Lukacs et al., 2005; Donnelly
and Barnes, 2006) (Fig. 2). Therefore, inhibition of chemokine signaling such as chemokine-
receptor antagonists would be a potential approach for COPD therapy.
CXCL1 (GROα) and CXCL8/IL-8 are produced by both structural and inflammatory cells
including macrophages. Both of these chemokines bind to their receptor CXCR2 whereas
CXCL8/IL-8 binds also to CXCR1. CXCL5 (epithelial cell-derived neutrophil-activating
peptide-78) is derived predominatly from epithelial cells and also activates CXCR2. CXCR1
and CXCR2 are expressed on neutrophils while CXCR2 is also expressed on other
inflammatory cells including a subset of CD8+ T cells, mast cells and macrophages.
CXCL1, CXCR5, and CXCL8 are chemotactic and activate inflammatory cells while
CXCL8/IL-8 induces neutrophils to degranulate, and causes an oxidative burst. The levels of
CXCR1, CXCR5, and CXCR8 were significantly increased in induced sputum and BAL
fluid of patients with COPD compared with normal smokers and non-smokers (Keatings et
al., 1996; Morrison et al., 1998; Soler et al., 1999; Traves et al., 2002). Neutralization of
CXCL8 with a blocking antibody significantly reduced the neutrophil chemotactic activity
of sputum form patients with COPD (Beeh et al., 2003). However, this antibody had little
clinical effect in patients with COPD (Mahler et al., 2004) promoting the study of small
molecular inhibitors of CXCR2 for therapy against the progression of COPD (Widdowson et
al., 2004). In mice exposed to acute cigarette smoke, a CXCR2 antagonist (SCH-N)
decreased the neutrophilic inflammatory response in lungs, however the compound itself
caused neutropenia (Thatcher et al., 2005). At present, CXCR2 antagonists are undergoing
Phase I and II trials, the efficacy of these treatments can be assessed once these trials have
been reported.
The levels of CXCR3 chemokines CXCL9 (monokine induced by IFN-γ), CXCL10 (IFN-γ
inducible protein 10, IP-10), and CXCL11 (IFN-inducible T-cell α chemoattractant) were
significantly increased in the sputum of patients with COPD when compared with non-
smokers but not with chronic smokers without airway obstruction (Costa et al., 2008) (Fig.
2). Furthermore, increased expression of these chemokines receptor (CXCR3) and its ligand
(CXCL10) have been shown in the lungs of COPD patients (Saetta et al., 2002; Hardaker et
al., 2004). Interestingly, most CXCR3 positive cells coexpressed CD8+ T cells in lungs of
COPD patients (Saetta et al., 2002). Moreover, a basal-to-apical gradient of CXCL11 across
the epithelium was markedly increased in lungs of patients with COPD, and this increase
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may stimulate transepithelial migration of T lymphocytes across the intact bronchial
epithelial monolayers suggesting that an increase in CXCR3 chemokines may lead to T
lymphocytes accumulation in COPD (Porter et al., 2008). CXCR3 are also expressed on B-
lymphocytes and hence may account for increased B-cell follicles that are associated with
more severe COPD (Hogg et al., 2004b).
CCL2 (monocyte chemotactic protein-1, MCP-1) is produced by a variety of cells including
macrophages, T cells and epithelial cells, and can activate CCR2 on monocyte and T cells.
The level of CCL2 was increased in the sputum, BAL fluid and lung of patients with COPD
(Capelli et al., 1999; de Boer et al., 2000; Traves et al., 2002) suggesting an important role
of CCL2 in the pathogenesis of COPD. CCL2 is also involved in tissue remodeling. CCL2
and its receptor (CCR2) are shown to be directly involved in endothelial and lung epithelial
cell proliferation, migration and wound closure in vitro (De Boer et al., 2007a; De Boer et
al., 2007b). In addition, CCL2 stimulates collagen synthesis in rat lung fibroblasts via a
TGFβ1-dependent pathway and hence potentially contribute to a fibrogenic remodeling as
seen in COPD. Recent studies demonstrated that CCR5 level was increased in lungs of
COPD patients, and silencing of CCR5 attenuated cigarette smoke-induced lung
inflammation and emphysema in mouse (Bracke et al., 2007; Costa et al., 2008). It is
important to note that the enhanced immune response occurred in CCR5-deficient mice
which may be due to the higher production of the CCR5 ligands, the overexpression of other
pro-inflammatory cytokines (e.g., IL-6, IL-8) and the involvement of CCR5 in T cell
apoptosis (Algood and Flynn, 2004; Mojtahedi, 2006; Murooka et al., 2006). However, it
remains to be seen whether CCR5 plays the same role in other animal models of COPD/
emphysema, and CCR5 (or CCR2/CCR5) antagonist has any beneficial effects in COPD.
CX3CL1 (fractalkine or mouse neurotactin) is the unique member of the CX3C chemokine
subfamily. In contrast to other chemokines, it exists in two forms, each mediating distinct
biological actions. The membrane-anchored protein, which is expressed primarily on the
inflamed endothelium, epithelial cells, dendritic cells, and neurons, serves as an adhesion
protein promoting the retention of monocytes and T cells. The soluble form resembles more
a conventional chemokine and strongly induces chemotaxis. Chemotaxis and adhesion are
mediated by the G protein-coupled receptor CX3CR1 that is expressed by cytotoxic effector
CD8+ and CD4+ T lymphocytes in addition to γδT lymphocytes, NK cells, dendritic cells,
and monocytes (Combadiere et al., 1998a; Combadiere et al., 1998b; Niess et al., 2005).
Recent studies showed that gene expression of CX3CL1 was increased in lungs of smokers
with COPD, and mouse lungs in response to chronic cigarette smoke exposure (Ning et al.,
2004; McComb et al., 2008). This was associated with recruitment and accumulation of
CX3CR1+ T lymphocytes and macrophages in the lungs. Therefore, one function of the
CX3CR1-CX3CL1 pathway is to recruit and sustain divergent immune cell populations
implicated in the pathogenesis of cigarette smoke-induced emphysema.
NF-κB pathways in cigarette smoke-mediated lung inflammatory response
As mentioned in preceeding paragraphs, the levels of proinflammatory cytokines and
chemokines are increased both locally in the lung and systemically in plasma in patients
with COPD. Although many transcription factors are involved in the regulation of these
inflammatory proteins, NF-κB is of particular importance (Christman et al., 2000). The
genes for these pro-inflammatory mediators which have been involved in inflammatory
process of the airways in COPD, including IL-1, IL-6, IL-8, MCP-1, and TNF-α which are
all regulated by NF-κB. Indeed, the numbers of RelA/p65-positive epithelial cells and
macrophages and RelA/p65 nuclear expression were increased in smokers and patients with
COPD (Di Stefano et al., 2002; Yagi et al., 2006; Rajendrasozhan et al., 2008b).
Furthermore, in COPD patients the number of RelA/p65-positive epithelial cells and
macrophages correlated with the degree of airflow limitation (Di Stefano et al., 2002). This
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suggests that NF-κB activation plays an important role in chronic inflammatory response
seen in COPD. The activation of NF-κB in lungs of patients with COPD is associated with
increased oxidative stress, due to the fact that NF-κB activating upstream kinases are redox-
sensitive (Bowie and O’Neill, 2000; Pantano et al., 2006).
The activation of NF-κB transcription factors occurs through two main pathways: the
canonical and the alternative pathways (Fig. 3). During canonical signaling upstream
mediators activate the IκB kinase (IKK) complex, composed of the two catalytic subunits
IKK-α and IKK-β and a third structural subunit, IKK-γ, to phosphorylate inhibitory IκB
proteins, leading to their ubiquitination and degradation. This leads to the disassociation of
RelA/p65 with IκB and translocation of RelA/p65 into nucleus. RelA/p65 can be
phosphorylated by a number of kinases such as protein kinase A (PKA) and mitogen- and
stress-activated protein kinase (MSK)1 (both at serine 276), IKK-β (at serine 536) and
protein kinase C (PKC)ζ (serine 311), each of which leads to an increase in RelA/p65’s
ability to induce cytokine release (Yang et al., 2003;Chen and Greene, 2004). This is
because phosphorylation of the RelA/p65 subunit facilitates binding of CBP/p300, which is
able to acetylate RelA/p65 at lysines 218, 221, and 310. In particular, acetylation of lysine
310 is important in pro-inflammatory gene transcription. Previously, we have shown that
cigarette smoke exposure induced the inflammatory cells influx which was associated with
increased levels of various NF-κB-dependent pro-inflammatory mediators in lungs, and
IKK-β inhibitors attenuated cigarette smoke extract-induced NF-κB-dependent pro-
inflammatory mediators release from peritoneal macrophages and monocyte-macrophage
MonoMac6 cells (Yang et al., 2006;Yao et al., 2008b). The alternative or noncanonical
pathway requires the NF-κB-inducing kinase (NIK), which cooperates with IKK-α to induce
the processing of the p100 C-terminus (termed IκBδ), which results in the nuclear
translocation of p52:RelB (Senftleben et al., 2001;Yin et al., 2001;Xiao et al., 2004).
Cigarette smoke exposure increased the levels of p52, RelB, IKK-α and NIK as well as RelB
interaction of p52 with NIK in mouse lung (Yang et al., 2008;Yang et al., 2009). This was
associated with recruitment of RelB on the promoter of pro-inflammatory genes suggesting
that alternative NF-κB pathway also participates in cigarette smoke-mediated lung
inflammatory response (Yang et al., 2008). Furthermore, cigarette smoke-mediated NF-κB
activation (increased phosphorylated ser276 and acetylated lys310 on RelA/p65, nuclear
level of RelB, and IL-8 release) was augmented in MonoMac6 cells transfected with IKK-α
(Yang et al., 2008) implicating IKK-α is required for NF-κB activation by cigarette smoke.
This was consistent with previous studies which showed that the pro-inflammatory cytokine-
induced NF-κB-dependent transcription, and promoter activation was markedly decreased in
IKK-α deficient fibroblasts even though IκBα degradation and NF-κB in vitro DNA binding
activity were normal in these cells in response to TNF-α or IL-1 (Sizemore et al.,
2002;Anest et al., 2003;Yamamoto et al., 2003). Further study showed that cigarette smoke-
mediated activation of IKK-α caused histone modification (phosphorylation and acetylation
of histone 3) and recruited acetylated RelA/p65 and other co-activators such as CBP on
promoters of proinflammatory genes leading to sustained proinflammatory mediators release
(Yang et al., 2008). As another component of NF-κB pathway, RelB was also recruited on
proinflammatory genes promoters via NIK and/or IKK-α activation by cigarette smoke in
MonoMac6 cells. However, it is interesting to note that RelB was degraded rapidly by
proteolysis in B lymphocytes in response to cigarette smoke suggesting RelB is
differentially regulated by cigarette smoke in cell specific manner and speculating the pro-
and anti-inflammatory protective role of RelB which is cell type-specific (Yang et al.,
2009). Furthermore, RelB degradation in B cells may signal for RelA/p65 activation leading
to proinflammatory cytokines release, and/or alter the acquired immunity resulting in
abnormal/self antibody production.
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In addition to IKK, NF-κB activation is also regulated by MSK1 by phosphorylating RelA/
p65 (serine 276) and histone H3, to establish a transcription-competent promoter complex
(enhanceosome) (Vermeulen et al., 2003). Cigarette smoke extract increased the level of
MSK1 in MonoMac6 cells but its level was decreased in IKK-α-knockdown MonoMac6
cells (Yang et al., 2008) suggesting MSK1 may play an important role in IKK-α-mediated
NF-κB activation and chromatin modifications on proinflammatory gene promoters in
response to cigarette smoke (Fig. 2). However, further studies are required to confirm this
contention using knockdown or overexpression models of MSK1 in vitro and in vivo.
The PKC family of serine/threonine kinases is ubiquitously expressed and is divided into
three categories based on the cofactors required for their activation. The activation of
conventional PKC members is dependent on calcium and diacylglycerol, novel members are
calcium independent but activated by diacylglycerol, and the atypical family members do
not require calcium or diacylglycerol. Recent studies show that PKCζ, an atypical family
member of PKC, regulates the activation of NF-κB via activating IKK, stabilizing IκB-α,
and/or directly phosphorylating RelA/p65 (ser311) in lungs of mice intraperitoneally
injected with TNF-α, LPS or IL-1 (Leitges et al., 2001; Duran et al., 2003) (Fig. 3).
Importantly, activated PKCζ also participates in cigarette smoke extract-mediated apoptosis
in human fetal lung fibroblast (MRC-5) cells, and its expression is elevated in lungs of
patients with COPD (Park et al., 2008) suggesting PKCζ/IKK/NF-κB pathway plays an
important role in pathogenesis of COPD. Indeed, our preliminary data showing decreased
lung inflammatory response in PKCζ-knockout mice exposed to cigarette smoke or LPS
(Yao et al., unpublished data). These results suggested that PKCζ is an important modifier
of lung inflammatory response, and down-modulation of PKCζ may have novel therapeutic
potential in prevention of cigarette smoke-related lung diseases.
EPIGENETICS IN PATHOGENESIS OF COPD
Epigenetics is the term used to describe heritable changes in gene expression that is not
coded in the DNA sequence itself but it is governed by post-translational modifications in
histone proteins and DNA. These modifications include chromatin remodeling (histone
acetylation, methylation, ubiquination, phosphorylation, and sumoylation) and DNA
methylation.
Histone acetyltransferase and deacetylase in lung inflammation
The complex structure of chromatin consists of DNA wrapped around an octamer of core
histones, which is composed of two molecules of each of the histones H2A, H2B, H3, and
H4. Acetylation of lysine residues on the N-terminal tails of the core histone proteins results
in uncoiling of the DNA, allowing increased accessibility for transcription factor binding
leading to gene transcription (Imhof and Wolffe, 1998; Rahman et al., 2004; Ito et al.,
2007). It is known that acetylation of core nucleosomal histones is regulated by the opposing
activities of HATs and HDACs.
HATs in lung inflammation
HATs are divided into five families. These include the Gcn5-related acetyltransferase
(GNATs), the MYST-related HATS, p300/CBP HATs, the general transcription factor
HATs, which include the TFIID subunit TAF250, the nuclear hormone-related HATs SRC1
and ACTR (Carrozza et al., 2003). Of these, p300/CBP which is regulated by the p38 MAP
kinase pathway, is vital for the co-activation of several transcription factors including NF-
κB and AP-1 in the transcription machinery (Thomson et al., 1999). Thus, it is likely that
histone acetylation via CBP/p300 has a significant role in the activation of NF-κB/AP-1-
mediated gene expression for pro-inflammatory mediators (Kamei et al., 1996; Carrero et
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al., 2000). Interestingly, NF-κB also induces histone acetylation in a temporal manner
leading to the recruitment of other co-activators and remodeling complexes and the
induction of proinflammatory gene expression although it is, itself, acetylated by other
HATs (Ito et al., 2000; Ghosh and Karin, 2002; Lee et al., 2006). NF-κB-induced
acetylation occurs preferentially on histone H4, rather than histones H2A, H2B or H3, in
epithelial cells and is directed primarily towards lysine 8 and 12 at NF-κB responsive
regulatory elements on proinflammatory genes (Ito et al., 2000).
HDAC2 in lung inflammation
The family of HDAC enzymes consists of 17 isoforms grouped into four families (de Ruijter
et al., 2003). Class I HDACs (HDAC1-3 and 8) reside almost exclusively in the nucleus,
whereas class II HDACs (HDAC4-7, 9-10) are able to shuttle between the nucleus and
cytoplasm in response to certain cellular signals. The third HDAC family consists of sirtuins
1–6 and their function is not yet fully understood. HDAC11 belongs to class IV. A common
feature of HDACs is the ability to remove acetyl moieties from the ε-acetamido group on
lysine residues within histones, resulting in condensation of DNA thereby silencing gene
transcription. HDACs not only deacetylate histones but also have the ability to deacetylate
non-histone proteins such as NF-κB and thereby have the ability to regulate NF-κB-
dependent pro-inflammatory gene transcription (Sengupta and Seto, 2004). We have shown
that cigarette smoke-mediated reduction in HDAC2 was associated with increased levels of
total and acetylated RelA/p65, and indicated RelA/p65 interacts with HDAC2 and RelA/p65
becomes available or retained in the nucleus for pro-inflammatory gene transcription when
HDAC2 is decreased (Yang et al., 2006; Yao et al., 2008a). Furthermore, HDAC inhibitor
trichostatin A has been reported to enhance NF-κB-driven inflammatory gene transcription
in cell lines (Ito et al., 2000; Chen et al., 2001). Therefore, alteration of HDACs by cigarette
smoke leads to acetylation of histones and transcription factor such as NF-κB, resulting in
the increased transcription of proinflammatory genes (Yang et al., 2006; Adenuga et al.,
2008a; Adenuga et al., 2008b).
Importantly, there is a marked reduction of HDAC2 expression/activity in lung parenchyma,
bronchial biopsies and alveolar macrophages of patients with COPD, and this decrease is
correlated with disease severity and the intensity of inflammation (Ito et al., 2005). The
mechanism underlying the reduction of HDAC2 level/activity is associated with its
posttranslational modifications such as nitrosylation, phosphorylation and ubiquitination
leading to proteasome-dependent degradation particularly in response to cigarette smoke
(Galasinski et al., 2002; Adenuga et al., 2009), or due to oxidative/carbonyl modifications of
HDAC2 (Yang et al., 2006). HDAC2 is required for the anti-inflammatory effects of
glucocorticoids as reduced levels/activity of HDAC2 has been shown to occur in patients
with COPD with subsequent corticosteroid resistance (Ito et al., 2005). Elevation of HDAC
activity by curcumin and theophylline significantly enhanced steroids suppression of
induced IL-8 release in monocytes and alveolar macrophage from patients with COPD
which was blocked by the HDAC inhibitor trichostatin A (Cosio et al., 2004; Meja et al.,
2008). Furthermore, HDAC2 can deacetylate glucocorticoid receptor (GR), thereby enabling
the association of GR with RelA/p65, and subsequently attenuate pro-inflammatory gene
transcription (Ito et al., 2006). Therefore, restoration or attenuation of HDAC2 loss will
enhance glucocorticoid sensitivity by deacetylating the RelA/p65 and GR. Such restoration
is possible by reversing the posttranslational modifications of HDAC2 such as
decarbonylation or dephosphorylation via inducing aldehyde dehydrogenases/reducatases
and phosphatases, or inducing the antioxidant buffer systems using Nrf2 activators and
ECSOD mimetics.
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Sirtuin 1 (SIRT1) in lung inflammation
Sirtuin 1 (SIRT1) is a class III HDAC with anti-inflammatory, anti-aging/senescence, and
anti-apoptotic activity mediated by the deacetylation of histones and non-histone proteins
including transcription factor (FOXO, p53, and NF-κB) (Yang and Sauve, 2006). We have
shown that the level of SIRT1 is reduced in rat lungs and MonoMac6 cells (Yang et al.,
2007) and in lungs of human smokers and patients with COPD (Rajendrasozhan et al.,
2008b) implicating the pivotal role of SIRT1 in the pathogenesis of COPD. The reason for
SIRT1 reduction is due to its posttranslational modifications such as carbonylation and
phosphorylation leading to degradation in response to cigarette smoke/oxidative/carbonyl
stress (Caito et al., 2008; Rajendrasozhan et al., 2008b). Knockdown of SIRT1 with siRNA
leads to an increased activation of NF-κB and subsequent inflammatory response whereas
upregulation of SIRT1 by SRT1720 and resveratrol inhibited pro-inflammatory mediators
release in response to cigarette smoke exposure (Rajendrasozhan et al., 2008b) suggesting
modulation of SIRT1 with activators or endogenous regulators (Milne et al., 2007; Milne
and Denu, 2008) would be an approach for the intervention of COPD. This contention is
conformed by the study showing the attenuation of cigarette smoke-induced lung
inflammation in mice after SIRT1 activator (i.e. SRT2172) administration (Nakamaru et al.,
2009). The protection against lung inflammatory and injurious responses by SIRT1 is
associated with the deacetylation of RelA/p65 and negative regulation of MMP-9 in
response to cigarette smoke/oxidative stress (Chen et al., 2002; Yang et al., 2007; Nakamaru
et al., 2009). However, futher study is required to investigate whether SIRT1 regulates the
progression of COPD/emphysema using genetic/pharmacological approaches.
SIRT1 also deacetylates other transcription factors such as forkhead box class (FOXO3) and
p53 thereby regulating oxidative stress-induced cell cycle arrest, apoptosis and cellular
senescence which play an important role in the pathogenesis of COPD. We have shown that
FOXO3 is acetylated when SIRT1 is reduced in response to cigarette smoke exposure in
mouse lung (Rajendrasozhan et al., 2008a). Therefore, the study on SIRT1-FOXO3 pathway
will further elucidate the pathological mechanisms, and provide the possible therapeutic
targets for COPD. SIRT1 interacts with p53 and deacetylates its C-terminal regulatory
domain (Vaziri et al., 2001), whereas reduction of SIRT1 leads to increased acetylation of
p53 thereby increasing its pro-apoptotic function and cellular senescence (Vaziri et al.,
2001; Luo et al., 2004). Oxidative stress accelerates cellular senescence by accumulation of
acetylated p53 via decrease in the function of SIRT1 by NAD+ depletion (Furukawa et al.,
2007; Ota et al., 2007). Moreover, blockade of p53 by antisense oligonucleotides reversed
the inhibitory effect of SIRT1 on cellular senescence (Ota et al., 2007). Our previous study
showed that nuclear SIRT1 levels were decreased in vivo and in vitro in response to cigarette
smoke exposure (Yang et al., 2007), but it is not known if SIRT1-mediated regulation of
p53 (acetylation) plays a role in cigarette smoke-mediated apoptosis and senescence.
Similarly, SIRT6 is also implicated in inflammatory response, senescence and aging
(Michishita et al., 2008; Kawahara et al., 2009; Van Gool et al., 2009) and hence other
SIRT members gain equal credence in understanding the pathogenesis of COPD.
Endothelial cells dysfunction plays a pivotal role in pathogenesis of emphysema, and
cigarette smoke-induced emphysematous alveolar septa are almost avascular which is
associated with reduced expression of endothelial nitric oxide synthase (eNOS) and
endothelium dysfunction (Yamato et al., 1996; Kasahara et al., 2001; Edirisinghe et al.,
2008; Wright and Churg, 2008; Ferrer et al., 2009). Recent studies showed that SIRT1 is a
key regulator of vascular endothelial homeostasis controling angiogenesis, vascular tone and
endothelial dysfunction by regulating eNOS (Potente and Dimmeler, 2008a). Furthermore,
SIRT1 has been shown to bind to eNOS, and deacetylate lysines 496 and 506 in the
calmodulin-binding domain of eNOS leading to enhanced nitric oxide (NO) production
which is an essential for endothelial-dependent vasorelaxation, endothelial cell survival,
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migration and postnatal neovascularization (Mattagajasingh et al., 2007). It is interesting to
note that NO has been shown to activate the SIRT1 promoter leading to an increase of
SIRT1 mRNA and protein (Nisoli et al., 2005; Ota et al., 2008) indicating that a positive
feedback mechanism exists between SIRT1 and eNOS (Potente and Dimmeler, 2008b).
Furthermore, Thus, activating SIRT1 through small molecules may help to reset the activity
of eNOS during situations of endothelial dysfunction where NO availability is limited in
smokers (Michaud et al., 2006). Moreover, cigarette smoke-induced apoptosis of coronary
arterial endothelial cells and inflammatory response were attenuated by SIRT1
overexpression (Csiszar et al., 2008). Therefore, SIRT1 is a possible molecular target to
prevent and/or treat pulmonary and cardiovascular diseases including COPD (emphysema)
and atherosclerosis by protecting endothelial cells from stress-induced premature
senescence, apoptosis and inflammatory response.
Histone/DNA methylation in lung inflammation
Histones can be methylated on either lysine (K) or arginine (R) residues, which is catalyzed
by enzymes belonging to three distint families of protein-the PRMT1 family, the SET-
DOMAIN-containing protein family, and the non-SET-domains DOT1/DOT1L (Zhang and
Reinberg, 2001; Bannister and Kouzarides, 2005). It is belived that methylation of K or R
residues forms a binding site or interacting domain allowing other regulatory proteins to be
recruited. Unlike acetylation, which generally correlates with transcriptional activation,
histone lysine methylation can signal either activation or respression, depending on the sites
of methylation (Zhang and Reinberg, 2001). Furthermore, a cross-talk between different
histone modifications also controls gene transcription epigenetically (Cheung and Lau,
2005; Wang et al., 2008). Therefore, positive and negative cross-talks ultimately generate
the complex patterns of gene- or locus-specific histone marks which are associated with
distinct chromatin states, leading to transcriptional repression or activation.
DNA methylation is another mechanism associated with epigenetic silencing, and this effect
is in part mediated by recruitment of HDACs through the methyl-DNA binding motifs of
components of several HDAC-containing complexes (Nan et al., 1998). It has been shown
that methylation of the promoter regions in multiple genes has been reported in
adenocarcinomas and non-small cell lung cancer, and this methylation was associated with
tumor progression (Zochbauer-Muller et al., 2001). Therefore, determination of specific
gene DNA methylation may provide the useful markers for early detection and/or
chemoprotective intervention in cancer. Methylation of p16 promoter was frequent in
sputum of patients with COPD, and this methylation was significantly correlated with heavy
cigarette smoking suggesting DNA methylation is associated with cigarette smoke-mediated
lung diseases (Georgiou et al., 2007). However, little data is available about the histone/
DNA methylation in cigarette smoke-induced lung inflammation and emphysema. Further
studies on histone/DNA methylation will bring the prospect of new biomarkers and/or
treatment for COPD/emphysema.
CONCLUSIONS AND FUTURE DIRECTIONS
Oxidative stress is critical for lung inflammatory response to cigarette smoke/environmental
pollutants through the upregulation of redox-sensitive transcription factors, and induction of
autophagy and unfolded protein response. Hence, development of antioxidants/thiol agents
or other pharmacological agents such as enzyme mimetics-ECSOD or Nrf2 activator or
reversing its post-translational modifications by aldehyde dehydrogenases/reducatases to
boost the endogenous antioxidant system could be used to ameliorate chronic inflammatory
and injurious responses in COPD. Futher studies on canonical/alternative NF-κB pathway
and their upstream kinases will identify novel therapeutic targets for the intervention of
COPD. Since epigenetic modifications (histone acetylation/deacetylation and histone
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methylation) are thought to the mechanism for understanding abnormal inflammation in the
pathogenesis and steroid resistance in COPD, it is believed that epigenetic drugs will bring
novel avenues for treatment of COPD.
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Figure 1. Aldehyde/carbonyl stress in COPD
Cigarette smoke contains different carbonyl compounds which can carbonylate proteins
through direct amino acid oxidation or an indirect mechanism involving lipids oxidation
leading to formation of reactive aldehydes such as acrolein and 4-hydroxy-2-nonenal (4-
HNE). These aldehye-protein adducts will alter the function and stability of intracellular
(e.g. histone deacetylases, nuclear erythroid-related factor 2, or Keap1) or extracellular [e.g.
extracellular matrix (ECM)] proteins or cause a variety of cellular and biochemical effects
including immunogenicity thereby inducing lung inflammatatory and autoimmune
responses, and injury. DNP: 2,4-dinitrophenyl, denotes protein carbonylation.; DC: dendritic
cells.
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Figure 2. Inflammatory and immune cells involved in COPD
Exposure to cigarette smoke or other irritants activates macrophage and epithelial cells to
release chemokines which attract other inflammatory and immune cells including
neutrophils, T-cells, dendrtic cells (DC), and B-cells into the lungs. CXCL1 and CXCL8
chemokines act on CXCR2 to attract netrophils while CXCL9, CXCL10 and CXCL11
chemokines bind to CXCR3 to attract T-cells into lungs. Cigarette smoke-induced
recruitment of immature DC fails to induce appropriate T-cells response but instead leads to
predominantly CD8+ T-cells proliferation in lungs. Furthermore, prolonged exposure to
cigarette smoke leads to the accumulation of extracellular matrix fragments which are
presented by DC to T-cells activiating specific B-cells. This will result in the production of
auto-antibody, such as anti-elastin body leading to abnormal autoimmunity in lungs. These
inflammatory and immune cells release proteases, perforin, granzyme, and produce anti-self
antibody causing alveolar wall destruction. Neutrophil-derived elastase also causes mucus
hypersecretion. Epithelial cells and macrophages also release transforming growth factor-β
(TGF-β) leading to small airway remodeling.
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Figure 3. Mechanism of cigarette smoke-mediated activation of NF-κB and pro-inflammatory
gene transcription
Cigarette smoke-mediated oxidative stress can activate the IKK complex to phosphorylate
inhibitory IκB proteins, resulting in their ubiquitination and degradation. This leads to the
translocation of RelA/p65 into nucleus which is recruited on the promoter of pro-
inflammatory genes. Alternative NF-κB pathway is also activated in response to cigarette
smoke exposure through the cooperation of NIK with IKK-α to induce the processing of the
p100 C-terminus resulting in the nuclear translocation of p52:RelB. Furthermore, IKKα-
activated MSK1 in response to cigarette smoke induces NF-κB activation by
phosphorylating RelA/p65 and altering chromatin modification. PKCζ, an atypical family
member of PKC, regulates the activation of NF-κB via activating IKK, stabilizing IκB-α,
and/or directly phosphorylating RelA/p65 in response to stimuli. NIK, NF-κB inducing
kinase; IKK, IκB kinase; PKCζ, protein kinase Cζ.
Yao and Rahman Page 31
Toxicol Appl Pharmacol. Author manuscript; available in PMC 2012 July 15.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
